Last 36.05 INR
Change Today +0.05 / 0.14%
Volume 202.9K
ASTEL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:31 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

astec lifesciences ltd (ASTEL) Snapshot

Open
36.00
Previous Close
36.00
Day High
38.00
Day Low
35.20
52 Week High
03/7/14 - 43.15
52 Week Low
07/29/13 - 13.85
Market Cap
668.0M
Average Volume 10 Days
33.2K
EPS TTM
3.30
Shares Outstanding
18.5M
EX-Date
09/2/13
P/E TM
10.9x
Dividend
0.75
Dividend Yield
2.08%
Current Stock Chart for ASTEC LIFESCIENCES LTD (ASTEL)

Related News

No related news articles were found.

astec lifesciences ltd (ASTEL) Related Businessweek News

No Related Businessweek News Found

astec lifesciences ltd (ASTEL) Details

Astec LifeSciences Limited manufactures, sells, and exports agrochemicals and pharmaceutical intermediates in India. The company offers agrochemicals, such as tebuconazole, propiconazole, hexaconazole, difenoconazole, epoxiconazole, cyproconazole, flutriafol, tricyclazole, metalaxyl, lambda cyhalothrin, and imazethapyr; and pharmaceutical intermediates, including 2,4 dichloro acetophenone, 2-chloro and 4-fluoro acetophenone, 4-methyl phthalic anhydride, thio bis-4-chloro thymol, and 1,2-pentanediol. It also serves customers in the United States, Japan, Europe, and Asia. Astec LifeSciences Limited was founded in 1994 and is based in Mumbai, India.

Founded in 1994

astec lifesciences ltd (ASTEL) Top Compensated Officers

Chairman and Managing Director
Total Annual Compensation: 4.8M
Whole Time Director
Total Annual Compensation: 944.0K
Compensation as of Fiscal Year 2013.

astec lifesciences ltd (ASTEL) Key Developments

Astec Lifesciences Limited Announces Standalone and Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013

Astec LifeSciences Limited announced standalone and consolidated unaudited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the standalone company reported net sales of INR 472.871 million compared with INR 382.551 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 59.339 million compared with INR 35.363 million for the same period a year ago. Profit from ordinary activities before tax was INR 25.612 million compared with INR 6.760 million for the same period a year ago. Net profit was INR 22.614 million or INR 1.22 per basic and diluted share compared with INR 3.339 million or INR 0.20 per basic and diluted share for the same period a year ago. For the nine months, the standalone company reported net sales of INR 1,474.897 million compared with INR 1,083.178 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 184.318 million compared with INR 116.037 million for the same period a year ago. Profit from ordinary activities before tax was INR 91.413 million compared with INR 55.597 million for the same period a year ago. Net profit was INR 73.462 million or INR 3.96 per basic and diluted share compared with INR 37.257 million or INR 1.83 per basic and diluted share for the same period a year ago. For the quarter, the consolidated company reported net sales of INR 506.994 million compared with INR 405.578 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 59.519 million compared with INR 36.230 million for the same period a year ago. Profit from ordinary activities before tax was INR 24.298 million compared with INR 3.698 million for the same period a year ago. Net profit was INR 21.300 million or INR 1.15 per basic and diluted share compared with INR 0.277 million or INR 0.02 per basic and diluted share for the same period a year ago. For the nine months, the consolidated company reported net sales of INR 1,603.559 million compared with INR 1,172.697 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 189.147 million compared with INR 121.592 million for the same period a year ago. Profit from ordinary activities before tax was INR 88.559 million compared with INR 51.871 million for the same period a year ago. Net profit was INR 70.608 million or INR 3.90 per basic and diluted share compared with INR 33.205 million or INR 1.96 per basic and diluted share for the same period a year ago.

Astec LifeSciences Limited, Board Meeting, Jan 24, 2014

Astec LifeSciences Limited, Board Meeting, Jan 24, 2014. Agenda: To consider standalone and consolidated unaudited earnings results for the third quarter and nine months ended December 31, 2013.

Astec LifeSciences Limited Announces Unaudited Consolidated and Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2013

Astec LifeSciences Limited announced unaudited consolidated and standalone earnings results for the second quarter and six months ended September 30, 2013. For the quarter on standalone basis, the company reported net sales of INR 580.008 million compared to INR 385.301 million reported a year ago. Profit from operations before other income, finance costs and exceptional items was INR 73.121 million compared to INR 26.346 million reported a year ago. Profit from ordinary activities before tax was INR 39.584 million compared to INR 35.166 million reported a year ago. Net profit was INR 30.576 million or INR 1.69 per basic and diluted share compared to net profit of INR 26.367 million or INR 1.56 per basic and diluted share reported a year ago. For the six months on standalone basis, the company reported net sales of INR 1,001.432 million compared to INR 700.627 million reported a year ago. Profit from operations before other income, finance costs and exceptional items was INR 123.289 million compared to INR 80.675 million reported a year ago. Profit from ordinary activities before tax was INR 65.801 million compared to INR 48.837 million reported a year ago. Net profit was INR 50.849 million or INR 2.81 per basic and diluted share compared to net profit of INR 33.918 million or INR 2.00 per basic and diluted share reported a year ago. For the quarter on consolidated basis, the company reported net sales of INR 672.818 million compared to INR 441.165 million reported a year ago. Profit from operations before other income, finance costs and exceptional items was INR 80.940 million compared to INR 32.146 million reported a year ago. Profit from ordinary activities before tax was INR 43.612 million compared to INR 38.349 million reported a year ago. Net profit was INR 34.596 million or INR 1.91 per basic and diluted share compared to net profit of INR 28.030 million or INR 1.65 per basic and diluted share reported a year ago. For the six months on consolidated basis, the company reported net sales of INR 1,095.432 million compared to INR 767.113 million reported a year ago. Profit from operations before other income, finance costs and exceptional items was INR 127.894 million compared to INR 85.361 million reported a year ago. Profit from ordinary activities before tax was INR 64.217 million compared to INR 48.172 million reported a year ago. Net profit was INR 49.249 million or INR 2.66 per basic and diluted share compared to net profit of INR 32.927 million or INR 1.94 per basic and diluted share reported a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASTEL:IN 36.05 INR +0.05

ASTEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASTEL.
View Industry Companies
 

Industry Analysis

ASTEL

Industry Average

Valuation ASTEL Industry Range
Price/Earnings 6.9x
Price/Sales 0.3x
Price/Book 0.6x
Price/Cash Flow 2.9x
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTEC LIFESCIENCES LTD, please visit www.astecls.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.